Back to Journals » Drug Design, Development and Therapy » Volume 5

Review

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

       
Total article views   HTML views PDF downloads Totals
37,241 Dovepress* 19,588+ 5,803 25,391
PubMed Central* 17,653 5,340 22,993
Totals 37,241 11,143 48,384
*Since 23 November 2011
+Since July 2016

View citations on PubMed Central and Google Scholar